Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actelion's prospective, multi-center, double-blind, placebo-controlled, active-reference, multiple-dose levels, randomized, parallel-group Phase II study of orally-active CRTH2 antagonist met primary endpoint.
Subscribe to our email newsletter
The study recruited around 579 patients and has evaluated the efficacy and tolerability of various doses of CRTH2 antagonist in adult patients who were suffering from seasonal allergic rhinitis (hay fever) due to mountain cedar pollen.
Actelion CEO Jean-Paul Clozel said they are very pleased with the results of this study since, for the first time, they now have proof that CRTH2 antagonists can bring clinically relevant benefit to patients suffering from allergic rhinitis.
"This study complements the positive proof-of-mechanism study in asthma reported in 2009," Clozel said.
"Together, these studies provide substantial information that will guide us in the further development of this compound and our follow-up molecules in allergic disorders."